GENECADD

GEnetic NEtworks as a tool for anti-CAncer Drug Development

Coordinatore	KAROLINSKA INSTITUTET    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	Sweden [SE]
Totale costo	2˙500˙000 €
EC contributo	2˙500˙000 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2010-AdG_20100317
Funding Scheme	ERC-AG
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-03-01   -   2016-02-29

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	STOCKHOLMS UNIVERSITET  Organization address address: Universitetsvaegen 10 city: STOCKHOLM postcode: 10691 contact info Titolo: Dr. Nome: Esther Cognome: Edlundh-Rose Email: send email Telefono: +44 1865 617 337 Fax: 468164315	SE (STOCKHOLM)	beneficiary	572˙950.80
2	KAROLINSKA INSTITUTET  Organization address address: Nobels Vag 5 city: STOCKHOLM postcode: 17177 contact info Titolo: Mrs. Nome: Jill Cognome: Blomstrand Email: send email Telefono: +46 8 524 876 87	SE (STOCKHOLM)	hostInstitution	1˙927˙049.20
3	KAROLINSKA INSTITUTET  Organization address address: Nobels Vag 5 city: STOCKHOLM postcode: 17177 contact info Titolo: Prof. Nome: Ulf Thomas Edvard Cognome: Helleday Email: send email Telefono: 46852481530 Fax: 46852481425	SE (STOCKHOLM)	hostInstitution	1˙927˙049.20

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Although several therapies target cellular pathways, current small molecules drug discovery is based on identification of inhibitors to single proteins, without knowledge of whether they are the most advantageous target. The objective of this proposal is to develop a novel method for drug discovery, combining phenotypic cell based screens with functional genetic networks to determine the molecular mechanisms of numerous small molecule inhibitors. This method will enable identification of numerous distinct inhibitors of a particular pathway, as well as providing their molecular mechanism.

Cancer cells harbour gene mutations that make them more reliant on other cellular pathways for survival. Such cellular pathways can be targeted to selectively kill the cancer cells using the concept of synthetic lethality. In this project we want to identify inhibitors of homologous recombination to target cancer using synthetic lethality.

To establish a functional genetic network for homologous recombination, we will first identify all recombination proteins using multiple genome-wide RNAi screens. Then the synthetic sick or lethal interaction map between all recombination proteins is determined by co-depletion of these. Such synthetic sick or lethal network will identify numerous putative targets for anti-cancer treatment. Importantly, using this network for chemical-genetic functional interactions will assist in determinating of the molecular mechanisms of inhibitors. Chemical-genetic networks based on synthetic sickness or lethality can potentially change future drug discovery methods as well as providing new mechanistic insights into the field of toxicology.'